ConductScience.org, home

Paper15735166

The role of CA125 in clinical practice.

Moss EL and 2 others. J Clin Pathol, 2005. Cited by 225 papers, by iCite.

Cite this record

ConductScience Library. The role of CA125 in clinical practice. Papers, record 15735166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15735166

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The role of CA125 in clinical practice.
PubMed
Journal
J Clin Pathol
PubMed
Year
2005
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
225
iCite
Relative citation ratio, by iCite
5.08
iCite
Revised in PubMed
2026-01-28
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Moss ELE L
2Hollingworth JJ
3Reynolds TMT M

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CA-125 AntigenMajor topic
Family PracticeMajor topic
Laboratories, HospitalMajor topic
NeoplasmsMajor topic
Ovarian NeoplasmsMajor topic
Adult
Aged
England
Epidemiologic Methods
False Positive Reactions
Female
Hospitals, District
Hospitals, General
Humans
Male
Middle Aged
Predictive Value of Tests
Unnecessary Procedures
Utilization Review

Source PubMed

Download CSV of topics

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110580673Transvaginal color Doppler ultrasonography and CA-125 in suspicious adnexal masses.Int J Gynaecol Obstet1999https://conductscience.org/library/papers/10580673PubMed
210228907CA 125 in benign gynecological conditions.Int J Biol Markers1998https://conductscience.org/library/papers/10228907PubMed
310690535Serum tumor marker CA 125 is an early and sensitive indicator of veno-occlusive disease in children undergoing bone marrow transplantation.Clin Cancer Res2000https://conductscience.org/library/papers/10690535PubMed
410689006Differentiating tubal abortion from viable ectopic pregnancy with serum CA-125 and beta-human chorionic gonadotropin determinations.Fertil Steril2000https://conductscience.org/library/papers/10689006PubMed
510976473Ovarian cancer screening in the general population.Ultrasound Obstet Gynecol2000https://conductscience.org/library/papers/10976473PubMed
611135268Benign conditions associated with raised serum CA-125 concentration.J Surg Oncol2000https://conductscience.org/library/papers/11135268PubMed
711530955The value of Ca 125 in the evaluation of tuberculosis activity.Respir Med2001https://conductscience.org/library/papers/11530955PubMed
811925140The significance of serum CA 125 elevation in malignant and nonmalignant diseases.Gynecol Oncol2002https://conductscience.org/library/papers/11925140PubMed
912193930The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass.Am J Obstet Gynecol2002https://conductscience.org/library/papers/12193930PubMed
1012399347Lesson of the week: Hypothyroidism mimicking intra-abdominal malignancy.BMJ2002https://conductscience.org/library/papers/12399347PubMed
1112468346Ascites as a predictor of ovarian malignancy.Gynecol Oncol2002https://conductscience.org/library/papers/12468346PubMed
1212620910Cancer antigen 125 associated with multiple benign and malignant pathologies.Ann Surg Oncol2003https://conductscience.org/library/papers/12620910PubMed
1312748476CA 125 levels in the preoperative assessment of advanced-stage uterine cancer.Am J Obstet Gynecol2003https://conductscience.org/library/papers/12748476PubMed
1412926084Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.Anticancer Res2003https://conductscience.org/library/papers/12926084PubMed
157028788Reactivity of a monoclonal antibody with human ovarian carcinoma.J Clin Invest1981https://conductscience.org/library/papers/7028788PubMed
161934471CA-125 concentrations in malignant and nonmalignant disease.Clin Chem1991https://conductscience.org/library/papers/1934471PubMed
177557595Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses.Gynecol Oncol1995https://conductscience.org/library/papers/7557595PubMed
188778417Benign gynecologic conditions associated with a CA-125 level > 1,000 U/mL. A case report.J Reprod Med1996https://conductscience.org/library/papers/8778417PubMed
198760716Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses.Br J Obstet Gynaecol1996https://conductscience.org/library/papers/8760716PubMed
208836386The clinical value of tumour markers in the management of ovarian cancer.Ann Clin Biochem1996https://conductscience.org/library/papers/8836386PubMed

See all 25 referencesDownload CSV of references

Cited by136

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 225 citations.

PMIDTitleJournalYearIn PapersSource
42680694Small Extracellular Vesicle and Total Lipid Profiles Provide a Diagnostic Advantage Over CA-125 Across Ovarian Cancer Subtypes.J Extracell Vesicles2026https://conductscience.org/library/papers/42680694PubMed
42572185Current Advances of Molecular Biomarkers and Liquid Biopsies Techniques in Ovarian Cancer.Cancer Med2026https://conductscience.org/library/papers/42572185PubMed
42017079Elevated Cancer Antigen 125 (CA125) Levels in an Indian Male: A Diagnostic and Therapeutic Marker in Extrapulmonary Tuberculosis.Cureus2026https://conductscience.org/library/papers/42017079PubMed
41869223Preoperative Considerations for Uterine Fibroid Removal in Patients With Mayer-Rokitansky-Küster-Hauser Syndrome and Klippel-Feil Syndrome: A Case Report.Cureus2026https://conductscience.org/library/papers/41869223PubMed
41768202Hematological and Biochemical Predictors of Cancer Diagnosis: An Analytical Study from a Cancer-Enriched Clinical Cohort.Med Arch2025https://conductscience.org/library/papers/41768202PubMed
41624469Neural Network-Based Cancer Diagnosis from Routine Hematological and Biochemical Data: Performance, Target Leakage, and Clinical Implications.Acta Inform Med2025https://conductscience.org/library/papers/41624469PubMed
41463255Early Detection and Prevention of Ovarian Cancer.Cancers (Basel)2025https://conductscience.org/library/papers/41463255PubMed
41113343Case Report: Organ procurement in a DCD donor with ovarian thecoma: abdominal NRP enabled timely and safe resection, pathological confirmation, and successful kidney transplantation.Front Transplant2025https://conductscience.org/library/papers/41113343PubMed
40564899Sequential Plasma Metabolome and Proteome Analyses to Develop a Novel Monitoring Strategy for Patients with Epithelial Ovarian Cancer: A Pilot Study.Int J Mol Sci2025https://conductscience.org/library/papers/40564899PubMed
40514453Promises and pitfalls of multi-cancer early detection using liquid biopsy tests.Nat Rev Clin Oncol2025https://conductscience.org/library/papers/40514453PubMed
40502685Multi-analyte approach combining cfDNA sequencing and protein testing for early ovarian cancer detection.iScience2025https://conductscience.org/library/papers/40502685PubMed
40471347Nano optical (bio)sensing platforms for early detection of pediatric cancer.Mikrochim Acta2025https://conductscience.org/library/papers/40471347PubMed
40131661Plasma proteomes and metabolism with genome-wide association data for causal effect identification in ovarian cancer.Discov Oncol2025https://conductscience.org/library/papers/40131661PubMed
40014217Gynecologic Cancer Screening and Prevention: State of the Science and Practice.Curr Treat Options Oncol2025https://conductscience.org/library/papers/40014217PubMed
39715465Impact of clinical factors on accuracy of ovarian cancer detection via platelet RNA profiling.Blood Adv2025https://conductscience.org/library/papers/39715465PubMed
39669673The ameliorative effect of chrysin on ovarian toxicity caused by methidathion in female rats.Front Mol Biosci2024https://conductscience.org/library/papers/39669673PubMed
39115678Prevention of Ovarian Cancer: Where are We Now and Where are We Going?Curr Oncol Rep2024https://conductscience.org/library/papers/39115678PubMed
39062909Validation of an In Vitro Diagnostic Test for Endometriosis: Impact of Confounding Medical Conditions and Lesion Location.Int J Mol Sci2024https://conductscience.org/library/papers/39062909PubMed
38918474Machine Learning-Enhanced Extraction of Biomarkers for High-Grade Serous Ovarian Cancer from Proteomics Data.Sci Data2024https://conductscience.org/library/papers/38918474PubMed
38833451High-throughput viable circulating tumor cell isolation using tapered-slit membrane filter-based chipsets in the differential diagnosis of ovarian tumors.PLoS One2024https://conductscience.org/library/papers/38833451PubMed

See all 136 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
MUC1694025PubTator's text mininghttps://conductscience.org/library/genes/94025

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/15735166

GET https://conductscience.org/api/papers/v1/15735166/references?page=2